Clinical Pharmacokinetics

Clinical Pharmacokinetics is a peer-reviewed journal in clinical pharmacology published by Adis International (New Zealand), part of Springer Nature. Founded in 1976 and issued monthly, it is the major review journal in its field. The journal studies drug disposition in the human body, a subject integral to drug development and rational pharmacotherapy, with a 2025 impact factor of 4.0 and a five-year impact factor of 4.6.Clinical Pharmacokinetics（临床药代动力学）是Adis International（新西兰）出版、隶属 Springer Nature 的临床药理学领域同行评审期刊，创刊于 1976 年，按月出版，是该领域最主要的综述类期刊。该刊以药物在人体内的处置过程为研究对象，属于药物开发与合理药物治疗学不可分割的组成部分，2025 年影响因子为 4.0，五年期影响因子为 4.6。^[1]

Scope

• The journal positions itself as the major review journal in clinical pharmacokinetics. By publishing critical and comprehensive review articles together with clinically focused original research, it promotes the continuing development of clinical pharmacokinetics and pharmacodynamics for the improvement of drug therapy and for postgraduate education in clinical pharmacology and therapeutics.期刊自我定位为临床药代动力学领域的首要综述刊物，通过发表批判性与全面性的综述文章以及聚焦临床的原创研究论文，推动临床药代动力学与药效动力学的持续发展，以改进药物治疗并深化临床药理学与治疗学的研究生教育。*
• Topics open with leading articles and current opinions offering overviews of emerging areas and contentious issues, and extend to the clinical pharmacokinetics and relevant pharmacodynamics of both single drugs and drug classes, as well as the pharmacokinetic principles behind effective drug treatment of particular diseases.选题以领衔文章与当前观点为起点，提供对新兴领域与争议问题的概览；也涵盖单一药物与药物类别的临床药代动力学及相关药效动力学，以及特定疾病有效治疗背后的药代动力学原理。^[2]
• On the theoretical and methodological side the journal welcomes new concepts and principles in pharmacokinetics, the application of therapeutic drug monitoring to optimise therapy, and the prediction and avoidance of drug interactions, as well as new methodology in drug development and advances in drug delivery systems.理论与方法层面欢迎药代动力学的新概念与新原理、治疗药物监测在优化治疗中的应用，以及药物相互作用的预测与避免；药物开发的新方法学与给药系统的进展同样在收稿之列。*
• Clinical and regulatory topics include the optimisation of treatment for particular patient populations and the regulatory aspects of pharmacokinetics and pharmacodynamics with their practical implications.临床与监管层面的选题包括特定患者人群治疗的优化，以及药代动力学与药效动力学的监管问题及其实际影响。*
• As a review-led title it also publishes original research articles and letters to the editor. All manuscripts are subject to peer review by international experts, and articles may carry slide sets, videos and animations as digital features and may be accompanied by plain language summaries for non-specialist readers.作为综述主导型刊物，该刊同时刊发原创研究论文与致编辑的来信，全部稿件均交由国际同行评审，文章还可附带幻灯片组、视频与动画等增强型内容，并可附加面向非专业读者的通俗语言摘要。*

这组选题把该刊与其他药理刊物清楚区分开来。它关心的始终是药物在体内的定量命运，而非疾病机制本身或药物安全性；正是这一取舍，使其在药物研发监管要求不断细化的背景下，成为研究者查找剂量依据与暴露-效应关系的常用参考。同属 Adis 系列的姊妹刊 Drug Safety 以药物警戒与安全性为主题，与本刊在读者群和选题上互补而不重叠，两刊均由同一机构在新西兰出版。

History

• 1976: Founded by Adis International in Auckland, New Zealand, the journal has been review-led from the outset and has long been among the most densely cited titles in pharmacokinetics.1976 年：创刊，由 Adis International 在新西兰奥克兰推出，创刊以来长期以综述体裁为主，是药代动力学领域被引最密集的专业刊物之一。*
• The 1990s: Influence grew as pharmacokinetics shifted from a research instrument to a central element of drug registration and therapeutic monitoring, with submissions extending from Australasia to Europe and North America and the journal becoming a routine international submission.1990 年代：随药代动力学从研究工具转变为药物注册与治疗监测的核心环节而扩大影响，稿源从澳新西兰地区扩展至欧洲与北美，成为国际药理学界的常规投稿去向。*
• The 2000s: The journal was brought into the Springer publishing system, retaining the Adis brand and its New Zealand editorial base while gaining Springer's digital platform and distribution, with the impact factor staying above 5 and reaching 6.447 in 2020.2000 年代：并入 Springer 出版体系，在保留 Adis 品牌与新西兰编辑基地的同时纳入 Springer 的数字平台与传播网络，影响因子长期维持在 5 分以上，2020 年达到 6.447。*
• The 2020s: Monthly publication continued with a growing share of original research, volume 65 appearing in 2026 and a median time to first decision of 10 days, with a 2025 impact factor of 4.0.2020 年代：持续月刊出版并扩展原创研究比重，2026 年为第 65 卷，投稿至首次编辑决定的中位时长为 10 天，2025 年影响因子为 4.0。*

Editors

该刊采用与 Adis 系列其他刊物一致的编辑建制：常设编辑由出版方内部的专职编辑担任，负责技术性审核与流程推进，学术判断则交给一个规模很大的国际编委。这一分工使综述选题的邀稿与把关能够依托编委的专业网络，而非依赖单一主编的个人取向。

• Editors: The current editors are Amitabh Prakash, MD, MBBS and Anton van Rensburg, MSc, both at Adis International, responsible for initial screening, pre-submission enquiries and workflow management.常任编辑：现任编辑为 Amitabh Prakash 医学博士与 Anton van Rensburg 理学硕士，两人均任职于 Adis International，负责稿件的初步审查、投稿咨询与流程管理。*
• Associate editor: Dr Esther Bulloch, also at Adis International, assists with the assessment and editing of scholarly manuscripts.副编辑：副编辑为 Esther Bulloch 博士，同样常驻 Adis International，协助处理学术稿件的评估与编辑加工。*
• International board: Board members come from institutions including the University of Sydney (Australia), KU Leuven (Belgium), Amsterdam UMC (the Netherlands), the Hebrew University of Jerusalem (Israel), the University of Lausanne (Switzerland), Lausanne University Hospital (Switzerland), the University of South Carolina (USA), the University of Alberta (Canada), the Medical University of South Carolina (USA), Radboud University Medical Center (the Netherlands), Ferris State University (USA), Duke University (USA), the University of Lyon (France), Chapman University (USA), Freie Universitaet Berlin (Germany), Leiden University (the Netherlands) and the Chinese Academy of Sciences (China), covering drug metabolism, therapeutic drug monitoring, paediatric pharmacology and population pharmacokinetics.国际编委：编委成员来自多国机构，包括悉尼大学（澳大利亚）、鲁汶大学（比利时）、阿姆斯特丹大学医学中心（荷兰）、耶路撒冷希伯来大学（以色列）、洛桑大学（瑞士）、洛桑大学医院（瑞士）、南卡罗来纳大学（美国）、阿尔伯塔大学（加拿大）、南卡罗来纳医科大学（美国）、拉德布拉德大学医学中心（荷兰）、费里斯州立大学（美国）、杜克大学（美国）、里昂大学（美国）、卡拉马里大学（美国）、柏林自由大学（德国）、莱顿大学（荷兰）以及中国科学院（中国）等，覆盖药物代谢、治疗药物监测、儿科药理学与群体药代动力学等方向。*
• Complete roster: The full list of current editors, the associate editor and all international board members is given on the journal's editorial board page.完整名单：现任全部编辑、副编辑与国际编委成员的完整名单，以期刊官网的编辑页面为准。*